Triastek, a Chinese developer of pharmaceuticals produced with additive manufacturing (AM), announced that the company has completed the first in human (FIH) study of T21, a medication for ulcerative colitis (UC). As with all of its products, Triastek prints T21 with its proprietary Melt Extrusion Deposition (MED) platform.
Thus far, Triastek has placed a particular emphasis on designing drugs with geometries that can only be achieved via AM, primarily in order to control where a given medication is released once ingested, and the rate of release of the medication’s active ingredients in the patient’s system. Regarding T21, these features could lead to a breakthrough for individuals suffering from UC, as it is difficult for the oral medications currently on the market to target the colon, specifically.
Based on imaging results from the FIH study, Triastek has shown that upon consumption, T21 tablets are delivered and released directly to the colon. In addition to a breakthrough for UC patients, this could also be a significant accelerator for Triastek’s efforts to gain approval for a New Drug Application (NDA) for T21.
As I was told by Triastek’s CEO, Dr. Senping Cheng, “…[T21 can mitigate] potential side effects from systemic exposure [that could result] if the medicine was released elsewhere in the body.” Again, this means that using AM for pharmaceuticals could not only lead to all the potential supply chain advantages that have led companies in virtually every industry to start exploring AM: for pharmaceuticals specifically, AM could lead to better quality products right now.
Of course, this is easier said than done, with the regulatory process for medications taking place on a timescale that makes the aerospace sector look like a breeze. On the other hand, the supply shortages in the pharmaceutical industry have been more intractable than virtually any other industry in the last few years, so this could become a catalyst for an accelerated push to use new manufacturing techniques including AM. This is not to suggest that pharmaceutical regulations should be loosened, but rather that corporations and public agencies should work together to prioritize the use of AM and other automation technologies in the cases where positive results have been proven.
Along these lines, it is interesting that in 2022, global pharma giant Eli Lilly announced that it would collaborate with Triastek to research potential new applications for the MED platform. This is relevant here because in April, 2023, the FDA rejected Eli Lilly’s NDA for a new UC drug, mirikuzmab. Notably, the reason for the rejection was related to concerns the FDA had with Eli Lilly’s manufacturing operations in Branchburg, NJ, involving inadequate quality control.
Images courtesy of Triastek
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
You May Also Like
HP and Global Steel Giant ArcelorMittal Announce Strategic 3D Printing Collaboration
Fortune Global 500 company ArcelorMittal, the world’s second-largest supplier of steel, has announced a strategic collaboration with HP to develop new additive manufacturing (AM) applications for ArcelorMittal’s steel powders. Via...
3D Printing Webinar and Event Roundup: November 10, 2024
We’ve got another busy week ahead of webinars and events around the world! There are multiple open houses and conferences, advanced AM training, a 3D printer launch event, our own...
3D Printing News Briefs, November 9, 2024: Concept Car, Afloat 3D Printing, & More
In today’s 3D Printing News Briefs, we’ll start with business, as Anisoprint appointed AM industry veteran Tuan TranPham as President of the Americas and APAC. Then we’ll move onto automotive...
Don’t Miss the Big Finale: Why AMS’ CEO Panel is a Must-Stay Event
When it comes to the annual Additive Manufacturing Strategies (AMS) summit in New York, attendees are treated to plenty of panels, presentations, and insights over three packed days. From innovations...